In NSCLC, EMP1 was associated with clinical resistance of gefitinib [12], EMP2 gene silencing resulted in activation of ERK and JNK in NSCLC cells [13], and EMP3 expression was significantly lower in tumor tissues compared to healthy lung tissues [14]. This evidence concerns the gene MAPK8 and non-small cell lung carcinoma.